SG11201809396SA - A specific trifluoroethyl quinoline analogue for use in the treatment of apds - Google Patents
A specific trifluoroethyl quinoline analogue for use in the treatment of apdsInfo
- Publication number
- SG11201809396SA SG11201809396SA SG11201809396SA SG11201809396SA SG11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA
- Authority
- SG
- Singapore
- Prior art keywords
- ucb
- international
- apds
- ipd
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO I PCT omit IIl Hot 0 mu im iflo Hs (10) International Publication Number WO 2017/198590 Al (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/519 (2006.01) A61P 37/00 (2006.01) (21) International Application Number: PCT/EP2017/061567 (22) International Filing Date: 15 May 2017 (15.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1608797.5 19 May 2016 (19.05.2016) GB (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Al- lee de la Recherche, 1070 Brussels (BE). (72) Inventors: ALLEN, Rodger Anthony; c/o IPD, UCB Cell- tech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). ARMSTRONG, Martin John; c/o IP Department, UCB Biopharma SPRL, 60, Allee de la Recherche, 1070 Brussels (BE). CAVAZZANA, Marina; Institut Imagine - INSERM U1163, Laboratoire de lympho-hematopoiese humaine, 24, Boulevard du Montparnasse, 75015 PARIS (FR). KRACK- ER, Sven; Institut Imagine - INSERM U1163, Laboratoire de lympho-hematopoiese humaine, 24, Boulevard du Mont- parnasse, 75015 Paris (FR). MCHALE, Duncan Philip; c/ o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). PAYNE, Andrew Charles; c/o IPD, UCB Cell- tech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 1-1 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, O EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 00 1-1 KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) N (54) Title: A SPECIFIC TRIFLUOROETHYL QUINOLINE ANALOGUE FOR USE IN THE TREATMENT OF APDS 0 (57) : N- {(R)-1-[8-Chloro-2-(1-oxypyridin-3-y1)-quinolin-3-y1]-2,2,2-trifluoroethyll -pyrido[3,2-d]pyrimidin-4-ylamine is ef- \" fective in the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1608797.5A GB201608797D0 (en) | 2016-05-19 | 2016-05-19 | Therapeutic use |
PCT/EP2017/061567 WO2017198590A1 (en) | 2016-05-19 | 2017-05-15 | A specific trifluoroethyl quinoline analogue for use in the treatment of apds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809396SA true SG11201809396SA (en) | 2018-11-29 |
Family
ID=56369612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809396SA SG11201809396SA (en) | 2016-05-19 | 2017-05-15 | A specific trifluoroethyl quinoline analogue for use in the treatment of apds |
Country Status (18)
Country | Link |
---|---|
US (1) | US20190209567A1 (en) |
EP (1) | EP3458065A1 (en) |
JP (1) | JP2019516703A (en) |
KR (1) | KR20190009790A (en) |
CN (1) | CN109152783A (en) |
AR (1) | AR108500A1 (en) |
AU (1) | AU2017267172A1 (en) |
BR (1) | BR112018072450A2 (en) |
CA (1) | CA3023974A1 (en) |
CL (1) | CL2018003281A1 (en) |
CO (1) | CO2018013559A2 (en) |
EA (1) | EA201892638A1 (en) |
GB (1) | GB201608797D0 (en) |
IL (1) | IL262943A (en) |
MX (1) | MX2018013770A (en) |
RU (1) | RU2018144187A (en) |
SG (1) | SG11201809396SA (en) |
WO (1) | WO2017198590A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
WO2017044849A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
PE20181086A1 (en) | 2015-09-11 | 2018-07-05 | Dana Farber Cancer Inst Inc | ACETAMIDE HAVE THRIZOLODIAZEPINES AND USES OF THE SAME |
SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR082799A1 (en) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | DERIVATIVES OF QUINOLINE AND QUINOXALINE AS QUINASE INHIBITORS |
JP2017516799A (en) * | 2014-05-27 | 2017-06-22 | アルミラル・ソシエダッド・アノニマAlmirall, S.A. | Pharmaceutical use |
-
2016
- 2016-05-19 GB GBGB1608797.5A patent/GB201608797D0/en not_active Ceased
-
2017
- 2017-05-15 CA CA3023974A patent/CA3023974A1/en not_active Abandoned
- 2017-05-15 RU RU2018144187A patent/RU2018144187A/en not_active Application Discontinuation
- 2017-05-15 CN CN201780030825.XA patent/CN109152783A/en active Pending
- 2017-05-15 SG SG11201809396SA patent/SG11201809396SA/en unknown
- 2017-05-15 US US16/099,537 patent/US20190209567A1/en not_active Abandoned
- 2017-05-15 KR KR1020187036873A patent/KR20190009790A/en not_active Application Discontinuation
- 2017-05-15 EA EA201892638A patent/EA201892638A1/en unknown
- 2017-05-15 BR BR112018072450-5A patent/BR112018072450A2/en not_active Application Discontinuation
- 2017-05-15 MX MX2018013770A patent/MX2018013770A/en unknown
- 2017-05-15 EP EP17723388.9A patent/EP3458065A1/en not_active Withdrawn
- 2017-05-15 AU AU2017267172A patent/AU2017267172A1/en not_active Abandoned
- 2017-05-15 WO PCT/EP2017/061567 patent/WO2017198590A1/en unknown
- 2017-05-15 JP JP2018560052A patent/JP2019516703A/en active Pending
- 2017-05-17 AR ARP170101315A patent/AR108500A1/en unknown
-
2018
- 2018-11-12 IL IL262943A patent/IL262943A/en unknown
- 2018-11-19 CL CL2018003281A patent/CL2018003281A1/en unknown
- 2018-12-13 CO CONC2018/0013559A patent/CO2018013559A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL262943A (en) | 2018-12-31 |
EA201892638A1 (en) | 2019-06-28 |
CL2018003281A1 (en) | 2019-01-25 |
RU2018144187A3 (en) | 2020-06-19 |
MX2018013770A (en) | 2019-03-21 |
EP3458065A1 (en) | 2019-03-27 |
WO2017198590A1 (en) | 2017-11-23 |
JP2019516703A (en) | 2019-06-20 |
CO2018013559A2 (en) | 2019-02-28 |
CA3023974A1 (en) | 2017-11-23 |
BR112018072450A2 (en) | 2019-02-19 |
AR108500A1 (en) | 2018-08-29 |
AU2017267172A1 (en) | 2018-12-13 |
KR20190009790A (en) | 2019-01-29 |
CN109152783A (en) | 2019-01-04 |
GB201608797D0 (en) | 2016-07-06 |
US20190209567A1 (en) | 2019-07-11 |
RU2018144187A (en) | 2020-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809396SA (en) | A specific trifluoroethyl quinoline analogue for use in the treatment of apds | |
SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
SG11201901409YA (en) | Polymerizing composition, method of manufacture thereof and articles comprising the same | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201806852PA (en) | Protein purification | |
SG11201901468SA (en) | Antibodies with reduced binding to process impurities | |
SG11201810786RA (en) | [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201810940XA (en) | Methods of treating pancreatic cancer | |
SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
SG11201805900YA (en) | Inhibition of allergic reaction using an il-33 inhibitor | |
SG11201808650QA (en) | Methods of treating ocular conditions | |
SG11201900602XA (en) | Polymer-free drug eluting vascular stents | |
SG11201907159SA (en) | Treatment of hidradenitis suppurativa |